Since all this is coming together at about the same time ... COVID and HIV studies, it could be either they share the same label, or different containers/labels/trademarks. The FDA will determine this.
[Also, I would suppose as an example we will see at some point the manufacturers of HCquine adding COVID 19 with the others... Malaria, Lupus etc to the labels of that HCQ product.]
For those trials that are for specific indications are unique and in different phases of study, I would assume they each are considered separately with having different names and pricing.